Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have been moving lower in early trading. At the time of writing, the stock had slid down -8.30% since the open. This downward move has put the stock in the top loser category moving into the second half of the trading period.AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is seeing declines so far in today’s trading session. Shares are moving -8.30% lower on solid volume. The stock has landed on the top loser list for the day according to Finviz data.
AMAG Pharmaceuticals, Inc.(NASDAQ:AMAG)‘s stock has performed at -58.48% year to date. Breaking that down further, it has performed 7.04% for the week, -13.47% for the month, -12.95% over the last quarter, -28.82% for the past half-year and -52.85% for this last year.
The simple moving average is the most common method used to calculate the moving average of prices. It takes the sum of all of the past closing prices over a specific time period and divides the result by the number of prices used in the calculation. Increasing the number of time periods in the calculation is an effective way to ascertain the strength of the long-term trend and/or the likelihood that it might reverse. Some argue that this type of average is not necessarily useful because each data point in the series has the exact same impact on the result no matter where it occurs in the sequence. AMAG Pharmaceuticals, Inc.’s stock is -11.54% away from its 20-Day Simple Moving Average. Extending back, their stock is trading -23.08% from the 50-Day Simple Moving Average, looking even further back, they are trading -32.28% off of the 200-Day Simple Moving Average. In comparing the current level to recent highs and lows, the stock is -36.45% from the 50-Day High and 11.11% off the 50-day low. We should also note their 52-Week High and Low: the shares currently trade -64.02% away from their high and 11.11% from the low.
Considering the above information, analysts have given a consensus recommendation of 2.70. This is according to the brokerage firms polled by Thomson Reuters.